Trials of bevacizumab in breast cancer – a safety review

Bibliography

• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
   PubMed Web of Science ®Google Scholar
• Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8
   PubMed Web of Science ®Google Scholar
• Birk DM, Barbato J, Mureebe L, Current insights on the biology and clinical aspects of VEGF regulation. Vasc Endovascular Surg 2008;42:517-30
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-19
   PubMed Web of Science ®Google Scholar
• Bertino EM, Otterson GA. Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer. Lung Cancer 2010;70:233-46
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Langmuir VK, Sledge GW, A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30:117-24
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Yorozu K, Kurasawa M, Bevacizumab improves the delivery and efficacy of paclitaxel. Anticancer Drugs 2010;21:687-94
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76
   PubMed Web of Science ®Google Scholar
• Klencke BJ, Bhattacharya S, Samant MK, Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC). J Clin Oncol 2008;26(20 Suppl):abstract 1036
   Google Scholar
• Robert NJ, Dieras V, Glaspy J, RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-60
   PubMed Web of Science ®Google Scholar
• Smith IE, Pierga JY, Biganzoli L, First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Ann Oncol 2010;22:595-602
   PubMed Web of Science ®Google Scholar
• Lang I, Inbar MJ, Greil R, Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): preliminary safety data from the CECOG phase III TURANDOT trial. J Clin Oncol 2010;28(15s): abstract 1126
   Google Scholar
• Miller KD, Chap LI, Holmes FA, Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9
   PubMed Web of Science ®Google Scholar
• Tripathy D. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. Oncologist 2007;12:375-89
   PubMed Web of Science ®Google Scholar
• Brufsky A, Rivera RR, Hurvitz SA, Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2010;28(15): abstract 1021
   Google Scholar
• Brufsky A, Bondarenko IN, Smirnov V, RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. San Antonio Breast Cancer Symposium, 2009, oral presentation Available from: http://sabcs09.m2usa.com/sabcsol.html. 2009
   Google Scholar
• O'Shaughnessy J, Miles D, Gray RJ, A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 2010;28(15S): abstract 1005
   PubMedGoogle Scholar
• von Minckwitz G, Eidtmann H, Rezai M, Neoadjuvant chemotherapy with or without bevacizumab: primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44). Cancer Res 2010;70(Suppl 24): abstract S4-6
   Google Scholar
• Derleth C, Mayer IA. Antiangiogenic therapies in early-stage breast cancer. Clin Breast Cancer 2010;10(Suppl 1):E23-31
   PubMedGoogle Scholar
• Nielsen DL, Andersson M, Andersen JL, Kamby C. Antiangiogenic therapy for breast cancer. Breast Cancer Res 2010;12:209
   PubMedGoogle Scholar
• Sanborn RE, Sandler AB. The safety of bevacizumab. Expert Opin Drug Saf 2006;5:289-301
   PubMed Web of Science ®Google Scholar
• Higa GM, Abraham J. Biological mechanisms of bevacizumab-associated adverse events. Expert Rev Anticancer Ther 2009;9:999-1007
   PubMed Web of Science ®Google Scholar
• Sirohi B, Smith K. Bevacizumab in the treatment of breast cancer. Expert Rev Anticancer Ther 2008;8:1559-68
   PubMed Web of Science ®Google Scholar
• Miles DW, Chan A, Dirix LY, Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47
   PubMed Web of Science ®Google Scholar
• McKinney M, Daly R. ‘The more you look...' Adverse-events tools may underestimate numbers. Mod Healthc 2011;41:8-9
   Google Scholar
• Ranpura V, Pulipati B, Chu D, Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010;23:460-8
   PubMed Web of Science ®Google Scholar
• Nasim S, Sousa BA, Dent RA, Pritchard KI. A meta-analysis of risk of cardiovascular events in patients with metastatic breast cancer (MBC) treated with anti vascular endothelial growth factor (VEGF) therapy – bevacizumab. Cancer Res 2010;70(Suppl 24): abstract P6-12-01
   Google Scholar
• Hapani S, Sher A, Chu D, Wu S. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010;79:27-38
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Saltz LB, Van Cutsem E, Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 2011;29:1757-64
   PubMed Web of Science ®Google Scholar
• Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010;49:287-97
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Mayer EL, Je Y, Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011;29:632-8
   PubMed Web of Science ®Google Scholar
• Verma N, Swain SM. Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side? J Clin Oncol 2011;29:603-6
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:2137-43
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Morris PG, Dickler M, McArthur HL, Dose-dense adjuvant doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol 2009;27:6117-23
   PubMed Web of Science ®Google Scholar
• Miller KD, O'Neill A, Perez EA, Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: a trial of the Eastern Cooperative Oncology Group (E2104). J Clin Oncol 2008;26(20 Suppl): abstract 520
   Google Scholar
• Hart LL, Badarinath S, Waterhouse DM, A multicenter study of 3 docetaxel regimens with bevacizumab as adjuvant therapy for breast cancer (BC): preliminary results. J Clin Oncol 2008;26(20 Suppl): abstract 575
   Google Scholar
• Mayer EL, Miller KD, Rugo HS, A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer. J Clin Oncol 2008;26(20 Suppl): abstract 519
   Google Scholar
• Roman CD, Choy H, Nanney L, Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 2002;105:43-7
   PubMed Web of Science ®Google Scholar
• Erinjeri JP, Fong AJ, Kemeny NE, Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer 2011;117:1296-301
   PubMed Web of Science ®Google Scholar
• Kriegel I, Fourchotte V, Cottu PH, Wound healing and catheter thrombosis after implantable venous access device placement in 266 metastatic breast cancer patients treated with bevacizumab. Cancer Res 2010;70(Suppl 24): abstract P2-16-09
   Google Scholar
• Wedam SB, Low JA, Yang SX, Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:769-77
   PubMed Web of Science ®Google Scholar
• Golshan M, Garber JE, Gelman R, Does neoadjuvant bevacizumab increase surgical complications in breast surgery? Ann Surg Oncol 2010;18:733-7
   PubMed Web of Science ®Google Scholar
• Carpenter JT, Forero A, Falkson CI, Concurrent and sequential bevacizumab and preoperative chemotherapy in the treatment of locally advanced breast cancer: UAB 0493. Cancer Res 2010;70(Suppl 24): abstract P1-11-24
   Google Scholar
• Bose D, Meric-Bernstam F, Hofstetter W, Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 2010;11:373-82
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Saleh MN, Galleshaw JA, Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. Clin Breast Cancer 2010;10:275-80
   PubMed Web of Science ®Google Scholar
• Ramirez Merino N, Calvo V, Vidal M, Risk of gastrointestinal perforation in patients with metastatic breast cancer treated with bevacizumab: a meta-analysis. J Clin Oncol 2010;28(15S): abstract 1091
   Google Scholar
• Sher AF, Wu S. Effect of bevacizumab on the risk of chemotherapy-associated anemia in cancer patients: a meta-analysis. J Clin Oncol 2010;28(15S): abstract 9136
   Google Scholar
• Marinella MA, Markert RJ. Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs. Intern Med J 2009;39:826-34
   PubMed Web of Science ®Google Scholar
• Burki F, Badie K, Bartoli P, Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen. Br J Clin Pharmacol 2008;65:793-4
   PubMed Web of Science ®Google Scholar
• Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011;305:487-94
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Shah A. Guidelines for the management of side effect of bevacizumab in patients with colorectal cancer. Cancer Ther 2008;6:327-40
   Google Scholar
• Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist 2010;15:819-25
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31
   PubMed Web of Science ®Google Scholar
• Miles D, Harbeck N, Escudier B, Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2010;29:83-8
   PubMed Web of Science ®Google Scholar
• Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505-14
   PubMed Web of Science ®Google Scholar
• Grothey A, Sugrue MM, Purdie DM, Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26:5326-34
   PubMed Web of Science ®Google Scholar
• Hayes DF. Bevacizumab treatment for solid tumors: boon or bust? JAMA 2011;305:506-8
   PubMed Web of Science ®Google Scholar
• Burstein HJ. Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J Clin Oncol 2011;29:1232-5
   PubMed Web of Science ®Google Scholar
• Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010;11:1172-83
   PubMed Web of Science ®Google Scholar
• Etienne-Grimaldi MC, Formento P, Degeorges A, Prospective analysis of the impact of VEGF-A gene polymorphisms on pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br J Clin Pharmacol 2011;71:921-8
   PubMed Web of Science ®Google Scholar
• Mayer EL Shak S, Miller K, Prognostic value of genomic analysis after neoadjuvant chemotherapy for breast cancer. Cancer Res 2010;70(Suppl 24): abstract P3-10-13
   Google Scholar
• Padhani AR, Liu G, Koh DM, Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009;11:102-25
   PubMed Web of Science ®Google Scholar